Rare bacteria boosts immunotherapy in prostate cancer

June 7, 2018 by Will Doss, Northwestern University
A tumor that was not treated with CP1 (above) and a tumor that was treated with CP1 (below). T-cells are in red, indicating immune response. Credit: Northwestern University

A unique bacterial strain isolated from a patient with pelvic pain may represent a promising path to treating prostate cancer with immunotherapy, according to a Northwestern Medicine study published in Nature Communications.

The study demonstrated how the bacterial strain travels directly to the and induces low-level inflammation, boosting the effectiveness of immune inhibitor therapy. Jonathan Anker, a sixth-year student in the Medical Scientist Training Program (MSTP), was the lead author of the study.

"This is one of the few things we've seen that's enhanced the ability of immune checkpoint inhibitor therapy in ," Anker said.

Prostate is the second-leading cause of cancer death in men in the United States, but immune checkpoint inhibitors, which harness the body's immune system to attack cancer, are largely ineffective because it's an immunologically "cold" cancer, according to Anker.

"Immune checkpoint inhibitors are clinically beneficial in other cancers such as melanoma, renal carcinoma and lung cancer, but they haven't shown any success in prostate cancer because the just isn't there," he said.

However, the discovery of an exceptional bacteria in the lab of Praveen Thumbikat, Ph.D., the O'Connor Family Research Professor of Urology, gave Northwestern scientists a golden opportunity to affect the immune activity.

"We were investigating the role of bacteria in benign prostate pain, and we isolated this interesting E. coli strain from a patient," said Thumbikat, also an associate professor of Pathology and the co-senior author of the current study, along with Sarki Abdulkadir, MD, Ph.D., vice chair for Research in the Department of Urology and the John T. Grayhack, MD, Professor of Urological Research.

Thumbikat and members of his laboratory found this bacteria, later named CP1, was attracted to the prostate, homing in on the organ like a missile and causing minor inflammation and pain for about a month. They transferred CP1 into a variety of mice models, and found that it trafficked directly to the prostate again and again.

"There may be receptors mediating it in the prostate, but we don't know precisely what drives this prostate tropism," Thumbikat said.

Regardless of what was driving it, the scientists believed CP1 might be used to jump-start immune activity in the prostate, essentially reprogramming the prostate micro-environment to one more favorable to immune checkpoint therapy.

In a series of experiments, Anker found a combination of CP1 and an therapy called PD-1 more than doubled the median overall survival of mice models with prostate cancer, largely credited to beneficial increases in several measures of immune activity.

"For example, it seems to have an effect on immunogenic cell death and it changes the T-cell ratios to a more immune-activated phenotype," Thumbikat said. "It's causing all kinds of innate immune cells to be more active."

While increasing the effectiveness of immune therapy by generating immune activity is not a new idea, it's rare to find a single molecule or compound that will increase activity in a variety of measures, according to Anker. In addition, these findings demonstrate how tissue-specific microbes might help boost immune therapies across the board, not just in prostate cancer.

"How do you get these very efficacious immune checkpoint inhibitors to work in these immunologically cold cancers?" Anker said. "We think this sets the blueprint for how you could screen bacteria isolated from other tissues, and find a CP1-like bacteria that might work."

Explore further: Combined chemotherapy and immunotherapy shows promise for advanced prostate cancers

More information: Jonathan F. Anker et al. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy, Nature Communications (2018). DOI: 10.1038/s41467-018-03900-x

Related Stories

Combined chemotherapy and immunotherapy shows promise for advanced prostate cancers

April 29, 2015
Chemotherapy can be very effective against small prostate tumors. Larger prostate tumors, however, accumulate cells that suppress the body's immune response, allowing the cancer to grow despite treatment. Researchers at the ...

Combination immunotherapy effective for advanced prostate cancer

March 9, 2017
Advanced prostate cancer resistant to castration therapy appears to respond well to a combination of immune checkpoint blockades and treatments that target certain immune-busting cells commonly associated with poor patient ...

Could viruses take cancer immunotherapy to the next level?

January 3, 2018
Immunotherapy, which helps the body's immune system attack cancer, has revolutionized treatment for cancers such as melanoma and leukemia. However, many other kinds of cancer remain resistant. A new study led by researchers ...

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Cancer immunotherapy found safe in patients with rheumatologic diseases

January 24, 2018
In the largest single-center study of patients with rheumatologic diseases who were prescribed modern cancer immunotherapy with what are called immune checkpoint inhibitors, only a minority of patients experienced a flare ...

Tapeworm drug fights prostate cancer

November 15, 2017
Cancer researchers at the University of Bergen (UiB) in Norway have in the recent years experienced with hundreds of known drugs, to see how they influence cancer cells.

Recommended for you

Scientists discover chemical which can kill glioblastoma cells

August 15, 2018
Aggressive brain tumour cells taken from patients self-destructed after being exposed to a chemical in laboratory tests, researchers have shown.

PARP inhibitor improves progression-free survival in patients with advanced breast cancers

August 15, 2018
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over ...

Three scientists share $500,000 prize for work on cancer therapy

August 15, 2018
Tumors once considered untreatable have disappeared and people previously given months to live are surviving for decades thanks to new therapies emerging from the work of three scientists chosen to receive a $500,000 medical ...

New clues into how 'trash bag of the cell' traps and seals off waste

August 15, 2018
The mechanics behind how an important process within the cell traps material before recycling it has puzzled scientists for years. But Penn State researchers have gained new insight into how this process seals off waste, ...

RUNX proteins act as regulators in DNA repair, study finds

August 15, 2018
A study by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has revealed that RUNX proteins are integral to efficient DNA repair via the Fanconi Anemia (FA) ...

Chemicals found in vegetables prevent colon cancer in mice

August 14, 2018
Chemicals produced by vegetables such as kale, cabbage and broccoli could help to maintain a healthy gut and prevent colon cancer, a new study from the Francis Crick Institute shows.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.